OMB approves
this survey as amended by FDA's February 25 faxes and contingent
upon FDA re-submitting for approval the full set of prescription
and OTC drug label information sheets before fielding this survey.
In particular, FDA agreed to make the label information sheets
consistent with the most current OTC label formats and to not
provide financial incentives to respondents. Finally, FDA agreed
that the mall-intercept sampling methodology used in this survey
will not permit the results to be generalizable to the U.S.
population.
Inventory as of this Action
Requested
Previously Approved
02/29/2000
02/29/2000
1
0
0
480
0
0
0
0
0
The purpose of this study is to
examine gender differences in risk/benefit perception for a
hypothetical Rx and OTC drug.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.